Abbott’s i-STAT TBI cartridge has received clearance from the U.S. FDA to be used with whole blood, allowing doctors to help assess patients with suspected concussion at the patient’s bedside and obtain lab-quality results in 15 minutes. Previously, the tests to help with the assessment of TBI were only cleared for use with plasma or serum, requiring samples to be sent to a lab for processing and testing. This new clearance will enable testing to be performed in an array of new healthcare settings beyond hospital emergency departments including urgent care clinics with a certificate to perform moderate complexity tests. This is an important step toward a future where testing could be done outside traditional healthcare settings, such as on the sidelines of sporting events.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Court rules DexCom infringed one of three Abbott patents, Bloomberg Law reports
- FDA reports Abbott recalls HeartMate Touch Communication System
- Abbott announces new data from studies with GLP-1 medicines and Freestyle Libre
- Abbott Declares 401st Consecutive Quarterly Dividend
- Abbott announces FDA voted in favor of its TriClip System